Disease Management
Type 2 diabetes patients' survival extended with valsartan vs. amlodipine
Published in Drug Week, February 6th, 2004
Valsartan patients also incurred lower total medical costs, an average $32,412 (26%) compared with amlodipine-treated patients.
D.G. Smith and colleagues at the University of Michigan published their findings in the January/February 2004 issue of the Journal of Managed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2004-02-06)
More Articles from Drug Week
- Homocystinuria
Sequence motif crucial for binding adenosyl derivatives - Acne
Atrisone completes pivotal phase III studies - Cardiovascular Disease Therapy
Should indications for CRT be expanded? - Cardiovascular Disease Therapy
Utility of endothelin-1 receptor blockade for heart failure patients reviewed - Cell Biology
Independent roles for insulin found in metabolism and cellular growth - Cell Biology
RNA interference of hypoxia inducible factor lessens its impact on cell growth - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
